Application of Mini-Programs in Long-Term Management of Epilepsy in Rural Areas

November 15, 2026 updated by: Xijing Hospital

Research on the Application of Mobile Health Management Mini-Programs in Long-Term Management of Epilepsy in Rural Areas

This project, titled " Research on the Application of Mobile Health Management Mini-Programs in Long-Term Management of Epilepsy in Rural Areas", is led by the First Affiliated Hospital of Air Force Medical University, with Jiang Wen as the principal investigator. It is a prospective, multicenter, cluster-randomized controlled trial involving 1276 patients from eight rural counties in China's northwest region. This study aims to establish a new scheme for improving epilepsy management in rural areas of Northwest China by combining remote mobile health management technology. The primary objective is to evaluate the effectiveness of the remote medical management model using a mobile health management mini-program in improving the self-management ability of rural epilepsy patients; secondary objectives include evaluating the impact of this model on patients' medication adherence, quality of life, health status, and frequency of epileptic seizures. Key components include patient and doctor interfaces for features like medication reminders, and seizure records. The trial runs from December 1, 2025, to November 30, 2028, with primary outcomes measured at 6 and12 months and secondary outcomes assessing medication adherence, quality of life, and safety.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shaanxi
      • Xi'an, Shaanxi, China, 710032
        • Department of Neurology, Xijing Hospital, Air Force Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 64 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Patient inclusion criteria:

  1. Meet the diagnostic criteria for epilepsy established by the International League Against Epilepsy (ILAE).
  2. Participate in the national rural epilepsy prevention and management project.
  3. Aged 18 to 64.
  4. The patient or their primary caregiver possesses a smartphone and is capable of using WeChat.
  5. Volunteer to participate in the study and sign a written informed consent form.

Patient exclusion criteria:

  1. Women who plan to become pregnant, are in pregnancy, or are breastfeeding.
  2. The seizures are caused by clear and reversible triggers.
  3. Those who have achieved epilepsy remission criteria and currently do not require long-term antiepileptic drug management.
  4. Severe infections, malignant tumors, severe dysfunction of heart, liver, and kidney functions, or severe physical diseases that the researcher believes will significantly affect epilepsy management, outcome evaluation, or follow-up completion.
  5. Individuals with severe mental, cognitive, or communication impairments who are unable to cooperate with research and remote management.
  6. It is expected that the participant will not be able to complete the required follow-up visits, or the investigator deems the participant unsuitable for participation in this study.
  7. Have participated in any other clinical trials within the past 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard Rural Epilepsy Management
Experimental: Enhanced Management with Mobile App

Patient Module: Real-time monitoring, medication reminders, seizure logging, educational resources.

Physician Module: remote follow-up, data analytics dashboard.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Epilepsy Self Management Scale Score
Time Frame: 6 and 12 months

Evaluation method: The Chinese version of the Epilepsy Self Management Scale was used. This scale includes multiple dimensions (such as drug management, information management, safety management, etc.), and a higher total score indicates stronger self-management ability.

6 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2025

Primary Completion (Estimated)

November 30, 2028

Study Completion (Estimated)

November 30, 2028

Study Registration Dates

First Submitted

December 21, 2025

First Submitted That Met QC Criteria

February 27, 2026

First Posted (Actual)

March 4, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • XJLL-KY-20252555

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD will not be shared due to privacy constraints, contractual agreements.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.